• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 4
  3. Author

Online ISSN: 2515-8260

Volume9, Issue4

Observation on Modified Radical Mastectomy with Adjuvant Chemotheraphy and Hormonal Therapy in the Management of Breast Cancer

    Dr. Rakesh Kumar Thakur, Dr. Vijay Shankar Prasad

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 4, Pages 864-874

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Breast cancer is the most common cause of cancer and cancer death worldwide. Although most patients present with localized breast cancer and may be rendered disease-free with local therapy, distant recurrence is common and is the primary cause of death from the disease. Adjuvant systemic therapies are effective in reducing the risk of distant and local recurrence, including endocrine therapy, anti-HER2 therapy, and chemotherapy, even in patients at low risk of recurrence. The widespread use of adjuvant systemic therapy has contributed to reduced breast cancer mortality rates. Adjuvant cytotoxic chemotherapy regimens have evolved from single alkylating agents to polychemotherapy regimens incorporating anthracyclines and/or taxanes. This review summarizes key milestones in the evolution of adjuvant systemic therapy in general, and adjuvant chemotherapy in particular. Although adjuvant treatments are routinely guided by predictive factors for endocrine therapy (hormone receptor expression) and anti-HER2 therapy (HER2 overexpression), predicting benefit from chemotherapy has been more challenging. Randomized studies are now in progress utilizing multiparameter gene expression assays that may more accurately select patients most likely to benefit from adjuvant chemotherapy.
Keywords:
  • PDF (253 K)
  • XML
(2022). Observation on Modified Radical Mastectomy with Adjuvant Chemotheraphy and Hormonal Therapy in the Management of Breast Cancer. European Journal of Molecular & Clinical Medicine, 9(4), 864-874.
Dr. Rakesh Kumar Thakur, Dr. Vijay Shankar Prasad. "Observation on Modified Radical Mastectomy with Adjuvant Chemotheraphy and Hormonal Therapy in the Management of Breast Cancer". European Journal of Molecular & Clinical Medicine, 9, 4, 2022, 864-874.
(2022). 'Observation on Modified Radical Mastectomy with Adjuvant Chemotheraphy and Hormonal Therapy in the Management of Breast Cancer', European Journal of Molecular & Clinical Medicine, 9(4), pp. 864-874.
Observation on Modified Radical Mastectomy with Adjuvant Chemotheraphy and Hormonal Therapy in the Management of Breast Cancer. European Journal of Molecular & Clinical Medicine, 2022; 9(4): 864-874.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 52
  • PDF Download: 84
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus